Cargando…
Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes
BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing blad...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543967/ https://www.ncbi.nlm.nih.gov/pubmed/37527159 http://dx.doi.org/10.1158/1055-9965.EPI-23-0331 |
_version_ | 1785114399514558464 |
---|---|
author | Chen, Ji-Qing Salas, Lucas A. Wiencke, John K. Koestler, Devin C. Molinaro, Annette M. Andrew, Angeline S. Seigne, John D. Karagas, Margaret R. Kelsey, Karl T. Christensen, Brock C. |
author_facet | Chen, Ji-Qing Salas, Lucas A. Wiencke, John K. Koestler, Devin C. Molinaro, Annette M. Andrew, Angeline S. Seigne, John D. Karagas, Margaret R. Kelsey, Karl T. Christensen, Brock C. |
author_sort | Chen, Ji-Qing |
collection | PubMed |
description | BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. METHODS: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival. RESULTS: Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93–0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23–1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04–1.41), neutrophil (HR = 1.04, 95% CI = 1.03–1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03–1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. CONCLUSIONS: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. IMPACT: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers. |
format | Online Article Text |
id | pubmed-10543967 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-105439672023-10-03 Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes Chen, Ji-Qing Salas, Lucas A. Wiencke, John K. Koestler, Devin C. Molinaro, Annette M. Andrew, Angeline S. Seigne, John D. Karagas, Margaret R. Kelsey, Karl T. Christensen, Brock C. Cancer Epidemiol Biomarkers Prev Research Articles BACKGROUND: Immune profiles have been associated with bladder cancer outcomes and may have clinical applications for prognosis. However, associations of detailed immune cell subtypes with patient outcomes remain underexplored and may contribute crucial prognostic information for better managing bladder cancer recurrence and survival. METHODS: Bladder cancer case peripheral blood DNA methylation was measured using the Illumina HumanMethylationEPIC array. Extended cell-type deconvolution quantified 12 immune cell-type proportions, including memory, naïve T and B cells, and granulocyte subtypes. DNA methylation clocks determined biological age. Cox proportional hazards models tested associations of immune cell profiles and age acceleration with bladder cancer outcomes. The partDSA algorithm discriminated 10-year overall survival groups from clinical variables and immune cell profiles, and a semi-supervised recursively partitioned mixture model (SS-RPMM) with DNA methylation data was applied to identify a classifier for 10-year overall survival. RESULTS: Higher CD8T memory cell proportions were associated with better overall survival [HR = 0.95, 95% confidence interval (CI) = 0.93–0.98], while higher neutrophil-to-lymphocyte ratio (HR = 1.36, 95% CI = 1.23–1.50), CD8T naïve (HR = 1.21, 95% CI = 1.04–1.41), neutrophil (HR = 1.04, 95% CI = 1.03–1.06) proportions, and age acceleration (HR = 1.06, 95% CI = 1.03–1.08) were associated with worse overall survival in patient with bladder cancer. partDSA and SS-RPMM classified five groups of subjects with significant differences in overall survival. CONCLUSIONS: We identified associations between immune cell subtypes and age acceleration with bladder cancer outcomes. IMPACT: The findings of this study suggest that bladder cancer outcomes are associated with specific methylation-derived immune cell-type proportions and age acceleration, and these factors could be potential prognostic biomarkers. American Association for Cancer Research 2023-10-02 2023-08-01 /pmc/articles/PMC10543967/ /pubmed/37527159 http://dx.doi.org/10.1158/1055-9965.EPI-23-0331 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Research Articles Chen, Ji-Qing Salas, Lucas A. Wiencke, John K. Koestler, Devin C. Molinaro, Annette M. Andrew, Angeline S. Seigne, John D. Karagas, Margaret R. Kelsey, Karl T. Christensen, Brock C. Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title | Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title_full | Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title_fullStr | Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title_full_unstemmed | Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title_short | Genome-Scale Methylation Analysis Identifies Immune Profiles and Age Acceleration Associations with Bladder Cancer Outcomes |
title_sort | genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543967/ https://www.ncbi.nlm.nih.gov/pubmed/37527159 http://dx.doi.org/10.1158/1055-9965.EPI-23-0331 |
work_keys_str_mv | AT chenjiqing genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT salaslucasa genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT wienckejohnk genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT koestlerdevinc genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT molinaroannettem genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT andrewangelines genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT seignejohnd genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT karagasmargaretr genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT kelseykarlt genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes AT christensenbrockc genomescalemethylationanalysisidentifiesimmuneprofilesandageaccelerationassociationswithbladdercanceroutcomes |